Pancreatic Elastase 1 Test · Stool

If you have been dealing with stubborn diarrhea, unexplained weight loss, greasy stools, or bloating after meals and your routine labs keep coming back normal, your pancreas may be quietly falling behind on its digestive job. Fecal pancreatic elastase-1 is the most widely used non-invasive way to check whether your pancreas is still producing enough enzymes to properly break down the food you eat.

The test is especially useful if you have chronic pancreatitis, cystic fibrosis, type 1 or type 2 diabetes, a history of pancreatic surgery, or long-standing digestive symptoms. A single stool sample can tell you whether pancreatic exocrine insufficiency (a condition where the pancreas does not release enough digestive enzymes) is likely contributing to what you are feeling.

What This Test Actually Measures

FE-1 (fecal elastase-1) is a digestive enzyme made by the pancreas and released into the small intestine with every meal. Unlike most pancreatic enzymes, it survives the trip through your gut almost unchanged, so the amount that shows up in a stool sample reflects how much your pancreas is actually producing. A low value suggests the pancreas is not keeping up. A normal value suggests it is.

The assay is specific to human elastase, so pig-derived enzyme pills (pancrelipase) do not interfere with the result. That matters if you are already on enzyme replacement and want to know what your own pancreas is doing underneath the therapy.

Why It Matters for Your Digestion

When your pancreas cannot make enough enzymes, fat, protein, and carbohydrates pass through your gut only partially digested. The result is usually a combination of loose or greasy stools, gas, cramping, weight loss, and nutritional deficiencies in fat-soluble vitamins. Left uncorrected, pancreatic exocrine insufficiency can quietly chip away at bone density, immune function, and energy levels over time.

Catching a low FE-1 early means you can start enzyme replacement before the nutritional damage compounds. In a real-world UK cohort of 1,027 people evaluated for pancreatic exocrine insufficiency, the condition was most common in chronic pancreatitis, pancreatic cancer, upper gastrointestinal surgery, and type 2 diabetes, showing that the populations most affected are often missed until symptoms become severe.

Chronic Pancreatitis

Chronic pancreatitis is the classic cause of low FE-1. As scarring accumulates in the pancreas, enzyme output drops and stool elastase falls. FE-1 is excellent at catching moderate to severe disease and poor at catching mild, early disease, which is an important distinction to keep in mind.

In a foundational study of 129 people with chronic pancreatitis at a cutoff of 200 micrograms per gram of stool, FE-1 correctly identified nearly everyone with moderate or severe pancreatic insufficiency but missed a meaningful share of those with mild insufficiency (sensitivity around 63% for mild disease). A follow-up study of 64 patients confirmed that FE-1 is not reliable for diagnosing mild to moderate chronic pancreatitis on its own. If your FE-1 is normal but symptoms point strongly at the pancreas, imaging and direct function tests are the next step.

Cystic Fibrosis

In cystic fibrosis, FE-1 is one of the most reliable non-invasive ways to classify whether someone is pancreatic sufficient or insufficient. A large multicenter study in cystic fibrosis validated cutoffs for distinguishing pancreatic sufficient from insufficient patients, with some analyses supporting a cutoff near 200 micrograms per gram. A rapid version of the same test showed 92.8% sensitivity and 96.6% specificity in 126 patients.

In children on newer CFTR modulator therapy (drugs that correct the underlying cystic fibrosis defect), FE-1 can rise substantially, and some patients regain pancreatic sufficiency. Starting therapy at a younger age and having a higher baseline FE-1 both predict a bigger improvement.

Diabetes and Metabolic Disease

Many people with type 1 and type 2 diabetes have quietly reduced pancreatic enzyme output. In one Irish cohort of 233 diabetic patients screened with FE-1, 12% had undiagnosed pancreatic exocrine insufficiency, with smoking as an added risk factor. In a larger study of 66 people with type 1 diabetes, low FE-1 was closely linked to steatorrhea (fat in the stool).

A retrospective analysis of 29,207 people found that having both diabetes mellitus and low fecal elastase was associated with a higher risk of pancreatic ductal adenocarcinoma (the most common form of pancreatic cancer). That combination is worth flagging, not ignoring.

Pancreatic Cancer and Post-Surgical Risk

In 194 people with advanced pancreatic cancer, a low FE-1 value was independently linked to poorer survival. In 136 people who had curative pancreatic cancer surgery, those with normal preoperative FE-1 had better disease-free survival than those with low values.

In 105 patients undergoing a pancreaticoduodenectomy (the Whipple procedure), preoperative FE-1 helped distinguish which of those with a soft pancreas actually developed a postoperative pancreatic fistula. About 30% of patients with a soft pancreas did not develop this complication, and FE-1 added risk stratification value before surgery.

Other At-Risk Populations

Low FE-1 shows up in several populations where the problem often flies under the radar.

• Older adults: in a study of 159 healthy adults without known gastrointestinal disease or diabetes, roughly 22% of those over 60 had FE-1 below 200 micrograms per gram.
• HIV on antiretroviral therapy: in a cohort of 100 people, pancreatic exocrine insufficiency was common, even when symptoms were not.
• HNF1B-related kidney disease (a genetic condition): in 134 patients, low FE-1 was common and sometimes symptomatic.
• Post-bariatric surgery: in 78 people followed for 2 years, 14 to 24% met criteria for moderate insufficiency.
• After acute pancreatitis: in 311 patients followed for 12 months, over one-third developed pancreatic exocrine insufficiency.

Reference Ranges

FE-1 reference ranges come primarily from adult studies using standard immunoassays, with cutoffs validated across chronic pancreatitis, cystic fibrosis, and diabetes cohorts. These are the most widely used research-based thresholds in stool, measured in micrograms per gram. Your lab may report slightly different cutpoints, and cystic fibrosis studies have validated cutoffs in a similar range from specific international cohorts.

Sources: de la Iglesia et al. 2025 meta-analysis; Vanga et al. 2018 meta-analysis; Loser et al. 1996; Lankisch et al. 1998. Compare your results within the same lab over time for the most meaningful trend.

When Results Can Be Misleading

FE-1 is a solid test, but a single reading can be distorted by a few predictable factors. Knowing these upfront keeps you from chasing a false alarm or missing a real problem.

• Watery or liquid stool: dilutes the sample and can falsely lower your result. If you are actively having profuse diarrhea, the test is less reliable and the value may need to be repeated once stools firm up.
• Non-pancreatic gut conditions: celiac disease, small bowel damage, short bowel syndrome, and decompensated liver disease can lower FE-1 without the pancreas itself being the primary problem. In 119 people with decompensated liver disease, FE-1 was often unreliable as a pure measure of pancreatic function.
• Borderline values between 100 and 200: day-to-day biological variability is roughly 15% in adults with chronic pancreatitis and up to 35% in some cystic fibrosis patients. A single borderline reading should be repeated before acting on it.
• Pre-test contamination: liquid stool samples are generally excluded from assay by labs because they cannot be reliably measured. Collect a formed sample when possible.

Pancreatic enzyme replacement therapy does not interfere with FE-1 because the assay specifically detects human elastase, and therapy pills use pig-derived enzymes. You can test while on enzyme replacement and still get a valid reading of your own pancreatic output.

Tracking Your Trend

A single FE-1 value tells you where you are today, but the trend over time tells you whether your pancreas is holding steady, declining, or recovering. This matters most if you have chronic pancreatitis, cystic fibrosis on CFTR modulators, diabetes, or recently had acute pancreatitis, since function can shift meaningfully over months to years.

A reasonable cadence is to get a baseline now, retest in 3 to 6 months if you are making a lifestyle change or starting a therapy that could affect pancreatic function, and then at least annually if you have a risk factor. Borderline values in the 100 to 199 range should always be repeated before acting on them, because day-to-day variability in this zone is meaningful.

What to Do with an Abnormal Result

A low FE-1 alone is not a diagnosis. It is a signal that warrants a structured next step rather than a wait-and-see approach. What that next step looks like depends on your symptoms and the size of the drop.

• If your value is below 100 micrograms per gram: this strongly suggests moderate to severe pancreatic exocrine insufficiency. A gastroenterologist should evaluate you with imaging (CT, MRI, or MRCP) to identify the cause, and pancreatic enzyme replacement therapy is typically the first-line treatment.
• If your value is between 100 and 199: repeat the test, and pair it with fat-soluble vitamin levels (A, D, E, K), a quantitative fecal fat measurement, and nutritional markers. Consider imaging if symptoms persist.
• If your value is normal but symptoms continue: FE-1 misses mild pancreatic exocrine insufficiency. Direct pancreatic function tests (secretin-stimulated testing), imaging, or an endoscopic pancreatic function test may be warranted, especially if you have risk factors like chronic alcohol use, family history of pancreatic disease, or type 1 diabetes.
• If you have diabetes and a low FE-1: given the higher pancreatic cancer risk flagged in large cohort data, imaging of the pancreas is worth discussing with a gastroenterologist.